The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
- PMID: 20015002
- DOI: 10.2174/1871520611009010064
The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
Abstract
Matriptase-2 is a newly identified member of the Type II Transmembrane Serine Protease (TTSP) family. The expression profile of many members of this family of proteases is frequently altered in cancerous cells and tissues and a number of TTSPs have been linked to cancer progression and development. Matriptase-2 is structurally similar to matriptase-1, a TTSP which has gained recent interest due to its potential to enhance the aggressive nature of cancer cells and its links with a variety of human cancers. Recently, matriptase-2 has been functionally linked to the regulation of iron metabolism; however, there is also evidence to suggest that, as with other members of the TTSPs, matriptase-2 may have a role in cancer development and progression. This article reviews the current literature on matriptase-2, together with its potential roles in physiological and disease states particularly focusing on cancer.
Similar articles
-
Type II transmembrane serine protease (TTSP) deregulation in cancer.Front Biosci (Landmark Ed). 2011 Jan 1;16(2):539-52. doi: 10.2741/3704. Front Biosci (Landmark Ed). 2011. PMID: 21196187 Review.
-
The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.Front Biosci. 2008 Jan 1;13:569-79. doi: 10.2741/2702. Front Biosci. 2008. PMID: 17981570 Review.
-
Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.Future Med Chem. 2019 Apr;11(7):743-769. doi: 10.4155/fmc-2018-0446. Epub 2019 Apr 4. Future Med Chem. 2019. PMID: 30945556 Review.
-
Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis.Blood. 2008 Sep 15;112(6):2539-45. doi: 10.1182/blood-2008-04-149773. Epub 2008 Jun 3. Blood. 2008. PMID: 18523150
-
The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.Oncol Rep. 2012 Oct;28(4):1491-7. doi: 10.3892/or.2012.1945. Epub 2012 Aug 2. Oncol Rep. 2012. PMID: 22858929
Cited by
-
TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.Cell Biol Int. 2018 Mar;42(3):273-280. doi: 10.1002/cbin.10832. Epub 2017 Aug 21. Cell Biol Int. 2018. PMID: 28762604 Free PMC article.
-
The role of TMPRSS6/matriptase-2 in iron regulation and anemia.Front Pharmacol. 2014 May 19;5:114. doi: 10.3389/fphar.2014.00114. eCollection 2014. Front Pharmacol. 2014. PMID: 24966834 Free PMC article. Review.
-
Mast Cell Targeted Chimeric Toxin Can Be Developed as an Adjunctive Therapy in Colon Cancer Treatment.Toxins (Basel). 2016 Mar 11;8(3):71. doi: 10.3390/toxins8030071. Toxins (Basel). 2016. PMID: 26978404 Free PMC article.
-
Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin.Protein Sci. 2024 Aug;33(8):e5110. doi: 10.1002/pro.5110. Protein Sci. 2024. PMID: 39073183 Free PMC article.
-
Iron refractory iron deficiency anemia.Haematologica. 2013 Jun;98(6):845-53. doi: 10.3324/haematol.2012.075515. Haematologica. 2013. PMID: 23729726 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources